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R
RDabigatran Is Not
a Direct Xa Inhibitor
Basra et al. (1) wrote a timely state-of-the-art paper on “safety
and efficacy of antiplatelet and antithrombotic therapy in acute
coronary syndrome patients with chronic kidney disease” in the
Journal.
As the authors stated, this is a relevant topic because of the
aging population we are treating and the associate decrease in
renal function they present. On the other hand, potent anti-
thrombotic treatment is the cornerstone therapy in acute
coronary syndrome. Therefore, it is mandatory to have a
thorough knowledge of how to safely use antiplatelet and
anticoagulant agents in patients with renal failure, and thus, this
paper is important for clinical practice.
However, there is a misconception in the last paragraph just
before “Conclusions.” The authors described dabigatran as
being a direct Xa inhibitor; however, dabigatran is an oral direct
IIa inhibitor. Besides, dabigatran is not included in Tables 2
and 3 of their report (1), which is a disappointment because
abigatran is already being used in clinical practice and its
ppearance in the tables would have been of interest.
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Reply
We thank Dr. Heras for her letter regarding our recent paper (1). We
agree that dabigatran was misclassified in the last paragraph as a direct
factor Xa inhibitor. As indicated in her letter, dabigatran is an oral
direct thrombin inhibitor. We plan to dedicate another review to the
impact of renal dysfunction on the safety and efficacy of this drug.
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